Naphthoic Acid

Naphthoic Acid

SCHEMBL4756576

O=C(O)c1cccc2ccccc12.c1ccc2[nH]cnc2c1.c1ccc2[nH]cnc2c1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.60
NR4A2 P43354 1/20 0.60
NR4A3 Q92570 1/20 0.60
CDC25B P30305 1/20 0.50
EGFR P00533 1/20 0.48
MAPK10 P53779 1/20 0.48
DDR1 Q08345 1/20 0.48
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 3/20 0.43
RAB9A P51151 2/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HTT P42858 1/20 0.43
PARP1 P09874 2/20 0.43
QPCT Q16769 1/20 0.43
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzimidazole SCHEMBL30988876 0.84 KMT2A (0.44) NR4A1NR4A2NR4A3MEN1KMT2A
Benzimidazole SCHEMBL28194023 0.84 RAB9A (0.47) KMT2AKDM4EALDH1A1RAB9AHPGD
Benzimidazole SCHEMBL28131872 0.82 ALDH1A1 (0.46) KMT2AKDM4EALDH1A1RAB9AHPGD
Benzimidazole SCHEMBL28132665 0.82 ALDH1A1 (0.46) KMT2AKDM4EALDH1A1RAB9AHPGD
Benzimidazole SCHEMBL1353216 0.82 CTNNB1 (0.46) EGFRMAPK10DDR1KDM4EALDH1A1
Salicylic Acid SCHEMBL11884489 0.81 ALDH1A1 (0.56) MEN1KMT2AKDM4EALDH1A1RAB9A
Salicylic Acid SCHEMBL11884485 0.81 ALDH1A1 (0.56) MEN1KMT2AKDM4EALDH1A1RAB9A
Benzimidazole SCHEMBL2496637 0.80 RAB9A (0.49) KMT2AKDM4EALDH1A1RAB9AHPGD
Phenanthrene SCHEMBL28066912 0.80 SMN1; SMN2 (0.48) MAPK10KDM4EALDH1A1RAB9AHPGD
Anthranilic Acid SCHEMBL9635430 0.79 KDM4E (0.46) MAPK10KMT2AKDM4EALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551902-B1 ANISOTROPIC FILMS BASED ON 1,8-NAPHTHOYLENE-1 ,2 -BENZIMIDAZOLE SULFONATES AND LYOTROPIC LIQUID CRYSTAL SYSTEMS AND METHODS FOR MAKING NITTO DENKO CORP (JP) 2008-09-10 EP disclosed
US-7262305-B2 Anisotropic films based on 1,8-naphthoylene-1′,2′-benzimidazole sulfonates and lyotropic liquid crystal systems and methods for making NITTO DENKO CORPORATION (JP) 2007-08-28 US disclosed
EP-1551902-A4 ANISOTROPIC FILMS BASED ON 1,8-NAPHTHOYLENE-1 ,2 -BENZIMIDAZOLE SULFONATES AND LYOTROPIC LIQUID CRYSTAL SYSTEMS AND METHODS FOR MAKING NITTO DENKO CORP (JP) 2006-05-17 EP disclosed
US-7026019-B2 Anisotropic films based on 1,8-naphthoylene-1′,2′-benzimidazole sulfonates and lyotropic liquid crystal systems and methods for making NITTO DENKO CORPORATION (JP) 2006-04-11 US disclosed
US-20060062932-A1 Anisotropic films based on 1,8-naphthoylene-1'2'-benzimidazole sulfonates and lyotropic liquid crystal systems and methods for making DUTOVA TATYANA Y 2006-03-23 US disclosed
EP-1551902-A2 ANISOTROPIC FILMS BASED ON 1,8-NAPHTHOYLENE-1 ,2 -BENZIMIDAZOLE SULFONATES AND LYOTROPIC LIQUID CRYSTAL SYSTEMS AND METHODS FOR MAKING Optiva, Inc. (US) 2005-07-13 EP disclosed
US-20040058091-A1 Anisotropic films based on 1,8-naphthoylene-1',2'-benzimidazole sulfonates and lyotropic liquid crystal systems and methods for making INSOLVENCY SERVICES GROUP, INC. 2004-03-25 US disclosed
WO-2004003599-A2 ANISOTROPIC FILMS BASED ON 1,8-NAPHTHOYLENE-1',2'-BENZIMIDAZOLE SULFONATES AND LYOTROPIC LIQUID CRYSTAL SYSTEMS AND METHODS FOR MAKING OPTIVA, INC. (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060062932-A1 Anisotropic films based on 1,8-naphthoylene-1'2'-benzimidazole sulfonates and lyotropic liquid crystal systems and methods for making LSS, LASP1, LYAR NR4A1 1564/4885NR4A2 3164/4885NR4A3 2683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.